Microdose Therapeutics is a pharmaceutical company specialized in the development of advanced drug delivery systems utilizing psychedelic APIs to treat mental health and cognitive degenerative diseases.
Location: United States, California, San Diego
Employees: 11-50
Founded date: 2020
Investors 3
| Date | Name | Website |
| - | Ambria Cap... | ambriacap.... |
| - | Empath Ven... | empath.vc |
| 16.01.2022 | Supernode ... | supernode.... |
Mentions in press and media 5
| Date | Title | Description |
| 16.12.2021 | Nova Mentis and Mycrodose Therapeutics Announce Major Milestone with Transdermal Technology for Fragile X Syndrome Clinical Program | VANCOUVER, BC, Dec. 16, 2021 /PRNewswire/ - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based th... |
| 14.12.2021 | Mycrodose Therapeutics Expands Scientific Advisory Board with the Addition of Dr. Yavorsky and Dr. Jacques | San Diego, California--(Newsfile Corp. - December 14, 2021) - Mycrodose Therapeutics ("Mycrodose"), a leading US pharmaceutical company developing advanced drug delivery technologies for use with psychedelic compounds, is pleased ... |
| 21.09.2021 | Mycrodose Therapeutics Successfully Completes Oversubscribed Private Placement to Expand Existing Patent Portfolio of Breakthrough Advanced Drug Delivery Technologies | Mycrodose Therapeutics successfully closes oversubscribed seven-figure financing round. Financing was funded by multiple high profile institutional investors, VCs, and Psychedelic Funds, including; The Conscious Fund, Negev Capital, Ambria ... |
| 02.09.2021 | Mycrodose Therapeutics Announces Expansion of Southern California Pharmaceutical Laboratory | San Diego, California--(Newsfile Corp. - September 2, 2021) - Mycrodose Therapeutics, a US pharmaceutical company focused on developing advanced drug delivery systems for use with psychedelic compounds, announced today the expansion of thei... |
| 20.08.2021 | Mycrodose Therapeutics Receives US DEA Schedule I License to Research Four (4) Psychedelic Compounds | Mycrodose Therapeutics an Advanced Drug Delivery Company “We are confident that our non-conventional drug delivery platforms will not only make the use of psychedelic drugs much safer but also increase the number of patients that can be tre... |